{"id":295556,"date":"2023-10-03T00:00:00","date_gmt":"2023-10-03T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acrecg0026-2023-biopharma-major-depressive-disorder-dsm-v-access-reimbursement-access\/"},"modified":"2026-03-31T10:32:04","modified_gmt":"2026-03-31T10:32:04","slug":"acrecg0026-2023-biopharma-major-depressive-disorder-dsm-v-access-reimbursement-access-reimbursement-major","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acrecg0026-2023-biopharma-major-depressive-disorder-dsm-v-access-reimbursement-access-reimbursement-major\/","title":{"rendered":"Major Depressive Disorder (DSM-V) &#8211; Access &#038; Reimbursement &#8211; Access &#038; Reimbursement &#8211; Major Depressive Disorder (US)"},"content":{"rendered":"<p>Numerous drugs from multiple drug classes are used as monotherapies and\/or adjunctive therapies to treat major depressive disorder (<abbr title=\"major depressive disorder\">MDD<\/abbr>). The prominent use of generically available drugs (e.g., selective serotonin reuptake inhibitors) as early-line treatments contributes to the market access challenges that branded therapies face when entering this market. Of note, brand-only drugs (e.g., Lundbeck \/ Takeda\u2019s Trintellix, Lundbeck \/ Otsuka Pharmaceutical\u2019s Rexulti) largely compete for use in treatment-resistant depression (<abbr title=\"treatment-resistant depression\">TRD<\/abbr>) patients. Nevertheless, given the high unmet need for effective treatments for inadequate responders to early-line therapies and treatment-resistant patients, newer-to-market drugs (e.g., Janssen\u2019s Spravato, Axsome Therapeutics\u2019 Auvelity) and late-phase emerging drugs (e.g., COMPASS Pathways\u2019 COMP360 psilocybin) seem promising. Although the expanding presence of generic drugs has given payers more leverage to control drug treatment costs in <abbr title=\"major depressive disorder\">MDD<\/abbr>, understanding the current and expected influence of clinical metrics and value-for-dollar on market access and medical practice is key for marketers and developers of new therapies for <abbr title=\"major depressive disorder\">MDD<\/abbr>.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>In this mature and highly generic treatment landscape, what actions can marketers of new therapies for <abbr title=\"major depressive disorder\">MDD<\/abbr> take to gain market access and thus ensure uptake?<\/li>\n<li>How do payer policies affect the prescribing of branded antidepressants (e.g., Lundbeck \/ Takeda\u2019s Trintellix, Janssen\u2019s Spravato) and branded oral atypical antipsychotics (i.e., Lundbeck \/ Otsuka Pharmaceutical\u2019s Rexulti, AbbVie\u2019s Vraylar) in this genericized market?<\/li>\n<li>What is the physician-reported treatment journey for <abbr title=\"treatment-resistant depression\">TRD<\/abbr> patients? How is it influenced by the market access and reimbursement environment for Spravato in <abbr title=\"treatment-resistant depression\">TRD<\/abbr>?<\/li>\n<li>How do payers expect to reimburse an emerging psychedelic therapy COMP360 psilocybin for <abbr title=\"treatment-resistant depression\">TRD<\/abbr>? What is the anticipated impact of payer restrictions \/ formulary placement on psychiatrists&#8217; prescribing of such a therapy for <abbr title=\"treatment-resistant depression\">TRD<\/abbr> patients?<\/li>\n<\/ul>\n<p><strong>CONTENT HIGHLIGHTS <\/strong><\/p>\n<p><strong>Geography:<\/strong> United States<\/p>\n<p><strong>Primary research:<\/strong> Survey of 101 U.S. psychiatrists, survey of 30 U.S. <abbr title=\"managed care organization\">MCO <\/abbr><abbr title=\"pharmacy director\">PD<\/abbr>s \/ <abbr title=\"medical director\">MD<\/abbr>s<\/p>\n<p><strong>Fingertip formulary: <\/strong>Formulary coverage and restrictions data for <abbr title=\"major depressive disorder\">MDD<\/abbr> therapies by commercial plans covering approximately 169.5 million lives nationally.<\/p>\n<p><strong>Key drugs covered: <\/strong>Trintellix, Spravato, Auvelity, Rexulti, Vraylar, Caplyta, COMP360 psilocybin, zuranolone<\/p>\n<p><strong>Content highlights:<\/strong><\/p>\n<p>Reimbursement and contracting.<\/p>\n<p>Access and prescribing.<\/p>\n<p>Opportunities and challenges for emerging therapies.<\/p>\n<p>Disease-specific special topic: Treatment-Resistant Depression.<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>U.S. Access &#038; Reimbursement<\/em> provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment. Each report includes up-to-date analyses of drug coverage and restriction policies as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies.<\/p>\n","protected":false},"template":"","class_list":["post-295556","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-major-depressive-disorder","biopharma-therapy-areas-psychiatry","biopharma-geography-us","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295556","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295556\/revisions"}],"predecessor-version":[{"id":576066,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295556\/revisions\/576066"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295556"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}